Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)